MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fped.2022.992932

Медицинская библиотека · Frontiers in pediatrics · 2022

Efficacy and safety of etanercept biosimilar rhTNFR-Fc in Chinese patients with juvenile idiopathic arthritis: An open-label multicenter observational study.

Xu Xuefeng, Liu Xiaohui, Zheng Wenjie, Xiao Jihong, Li Xiaozhong, Wu Ling, Zou Lixia, Ouyang Qian, Shangguan Yaoyao, Lin Kezhao, Dai Xiaomei, Chen Yuanling, Xu Yiping, Wu Jianqiang, Lu Meiping

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Etanercept biosimilar recombinant human TNF-α receptor II: IgG Fc fusion protein (rhTNFR-Fc) has showed its efficacy and safety in Chinese patients with rheumatoid arthritis. However, data on rhTNFR-Fc's application in juvenile idiopathic arthritis (JIA) is limited.

METHODS

A prospective, observational, multicenter study was performed at 6 institutes in China from July 2020 to December 2021. In a 24-week follow-up, patients with JIA including polyarticular JIA and enthesitis related arthritis received rhTNFR-Fc plus methotrexate (MTX) treatment. The primary outcome parameters were improvements of cJADAS-10 (clinical Juvenile Arthritis Disease Activity Score), and the secondary outcome parameter was an inactive disease.

RESULTS

60 patients completed at least 12-week follow-up, and 57 completed 24-week follow-up. They had high C reactive protein values (11.6 mg/L) and cJADAS-10 (14.6) at baseline. Thirteen patients had morning stiffness. 33 patients showed synovial thickening, and 34 showed bone marrow edemas on MRI. Ultrasonography demonstrated significant joint effusions in 43 patients. The cJADAS-10 sharply decreased from 14.66 at the baseline to 2.4 at 24 weeks of rhTNFR-Fc therapy, respectively (P < 0.01). About half of patients achieved inactive disease at 24 weeks of therapy. Compared with the baseline, the number of patients with morning stiffness, joint effusions, bone marrow edema and synovial thickening on MRI significantly decreased at 24 weeks. Adverse events were consistent with known side effects of biologic agents.

CONCLUSIONS

The present study indicated that the combination of rhTNFR-Fc and MTX significantly improve symptoms and disease activity of children with JIA. This study suggests etanercept biosimilar rhTNFR-Fc as an effective and safe therapy for children with JIA.

Для цитирования: Xu Xuefeng, Liu Xiaohui, Zheng Wenjie, Xiao Jihong, Li Xiaozhong, Wu Ling, Zou Lixia, Ouyang Qian, Shangguan Yaoyao, Lin Kezhao, Dai Xiaomei, Chen Yuanling, Xu Yiping, Wu Jianqiang, Lu Meiping. Efficacy and safety of etanercept biosimilar rhTNFR-Fc in Chinese patients with juvenile idiopathic arthritis: An open-label multicenter observational study.. Frontiers in pediatrics. 2022. DOI: 10.3389/fped.2022.992932.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.